|
One of the future challenges will consist of shortening the path from generating molecular research data to the treatment of a patient, to being able to offer a patient a therapy individually and optimally tailored to their genetic constitution or their desease subtype. The development of a medicine takes on the average 10 years and a corresponding costs of somewhere around € 500 million. Looking for potential cost savings can appropriately be found in computer-assisted methods. This sets the starting point for c.a.r.u.s. to develop high performance IT-solutions for information exchange and - processing.
IT as intelligent tools
During the development of a medicine one searches first for new active substances. In the past this was linked with the image of "the search for the needle in the haystack", detecting an active substance was by pure chance. Clearly, screening procedures were able to reduce the development time in active substance design. The screening for molecules and testing their effect on the target proteins delivers promising active substance candidates, that can be further researched. The haystack is thereby obviously minimized.
Download:
 ViSoR_Shortcut
 ViSoR Folder
 Pressinformation BIOTECHNCIA 2008
 Case Study_Intel
|
